Pharma channel feed

As spot­light trains on bio­phar­ma di­ver­si­ty, most com­pa­nies kept their C-suites ex­act­ly the same in 2020 — re­port

4 years ago

Bay­er clos­ing down San Fran­cis­co re­search hub as at­ten­tion turns to Berke­ley plan

4 years ago

Med­ic­aid com­mis­sion to Con­gress: In­crease re­bates for ac­cel­er­at­ed ap­proval drugs

4 years ago
FDA+

The Ko­dak in­sid­er trad­ing dra­ma con­tin­ues as CEO set for ques­tion­ing in NY state probe

4 years ago
People

Amid slug­gish sales and du­el­ing law­suits, No­var­tis bows out of Am­gen part­ner­ship, slash­es staff

4 years ago
Deals

Mis­sis­sip­pi sues Eli Lil­ly, Sanofi and No­vo over in­sulin prices as in­ter­change­able biosim­i­lars may ar­rive soon

4 years ago

Top an­a­lyst maps a rocky road for Ver­tex — un­less they adopt a $10B M&A cam­paign to save the pipeline

4 years ago
Deals

In next-gen BTK bat­tle, Ab­b­Vie and J&J tout piv­otal da­ta back­ing Im­bru­vi­ca as a com­bo treat­ment

4 years ago
R&D

Months af­ter FDA re­jec­tion, Sanofi touts piv­otal win for rare dis­ease drug su­tim­limab as it preps to re­file

4 years ago
R&D

Sen­a­tors lam­bast new Alzheimer’s drug’s price but give Janet Wood­cock a free pass on the ap­proval de­ci­sion

4 years ago

A sec­ond ad­comm mem­ber aban­dons his post in af­ter­math of con­tro­ver­sial ad­u­canum­ab de­ci­sion

4 years ago
FDA+

Bris­tol My­er­s' CAR-T Breyanzi busts out a win in ear­li­er-line lym­phoma, po­ten­tial­ly crack­ing open an ex­pand­ed mar­ket

4 years ago
R&D
Cell/Gene Tx

Cit­ing 'ex­ces­sive' ex­ec­u­tive com­pen­sa­tion, ad­vi­so­ry firms want a long­time Re­gen­eron board mem­ber oust­ed

4 years ago
People

UP­DATE: Will Bio­gen ever pub­lish the tri­al re­sults for its new Alzheimer’s drug?

4 years ago
FDA+

What does a clear ma­jor­i­ty of the bio­phar­ma in­dus­try think of the FDA ap­proval of ad­u­canum­ab? 'Hor­ri­fy­ing' 'Dan­ger­ous' 'Con­fus­ing' 'Dis­as­ter'

4 years ago

An­a­lysts hound Bio­gen with ques­tions over Aduhelm's $56K price point as news of Alzheimer's OK rip­ples through glob­al mar­kets

4 years ago

FDA re­jects Google's push to add vir­tu­al ex­am for Parkin­son’s dis­ease to its smart­watch

4 years ago
FDA+

End­points News poll: Let's get your opin­ion on that con­tro­ver­sial ad­u­canum­ab ap­proval

4 years ago

FDA OKs ad­u­canum­ab for Alzheimer's, turn­ing con­tro­ver­sial Bio­gen drug in­to a megablock­buster

4 years ago
R&D
FDA+

Un­der ‘threat’ of fines, No­var­tis sues HHS over drug pric­ing pro­gram

4 years ago

Glax­o­SmithK­line, As­traZeneca butt heads over li­cens­ing rights to key PARP in­hibitor — re­port

4 years ago

Bris­tol My­ers sued over $6B Cel­gene CVR as trustee claims 'bla­tant mis­con­duc­t' for liso-cel de­lays

4 years ago

#AS­CO21: As­traZeneca's Lyn­parza earns win in ear­ly breast can­cer pa­tients, crack­ing open post-surgery po­ten­tial

4 years ago
R&D

Af­ter ad­mon­ish­ing Ab­b­Vie for Hu­mi­ra patent and pric­ing, Sen Ron Wyden takes Richard Gon­za­lez to task on tax prac­tices

4 years ago
First page Previous page 238239240241242243244 Next page Last page
A service from the Financial Times